Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2323297 | 0.83 | MCHR1 (0.53) | MCHR1CYP2D6CHRM1HTR2A | |
| SCHEMBL12440322 | 0.77 | PDK1 (0.40) | MCHR1CNR2FFAR4CYP2D6CHRM1 | |
| SCHEMBL12440634 | 0.73 | CYP11B1 (0.38) | MCHR1CNR2MLNR | |
| SCHEMBL12441159 | 0.73 | PDK1 (0.45) | MCHR1DRD2DRD4CNR2 | |
| SCHEMBL2321696 | 0.72 | HTR7 (0.38) | DRD2DRD4DRD3 | |
| SCHEMBL4525699 | 0.71 | DRD4 (0.32) | DRD2DRD4DRD3 | |
| SCHEMBL12440001 | 0.70 | MCHR1 (0.44) | MCHR1CYP2D6CHRM1HTR2A | |
| SCHEMBL6232714 | 0.70 | MCHR1 (0.72) | MCHR1DRD3CYP2D6CHRM1 | |
| SCHEMBL12440750 | 0.70 | HRH3 (0.43) | MCHR1CHRM1HTR2A | |
| SCHEMBL6756330 | 0.69 | HRH3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357173-A1 | New alkyne compounds with MCH-antagonistic activity and medicaments containing them | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-08-17 | — | — | EP | disclosed |